Monepantel is under clinical development by PharmAust and currently in Phase II for Motor Neuron Diseases. According to GlobalData, Phase II drugs for Motor Neuron Diseases have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Monepantel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Monepantel overview

Monepantel is under development for the treatment of refractory solid tumors , neurodegenerative diseases, other non-cancer diseases, amyotrophic lateral sclerosis (ALS), motor neuron diseases and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through oral route. It acts by targeting p70S6K (70-kDa Ribosomal Protein S6 Kinase) and mTOR.

It was under development for ovarian cancer,

PharmAust overview

PharmAust (PAA) is a clinical-stage company that focuses on the development of targeted cancer therapeutics for the treatment of human and veterinary cancers. The company’s lead product candidate Monepantel is a small molecule that has been developed to treat parasite infections in food chain animals. MPL is an oral aminoacetonitrile compound that modulates the mTOR pathway. The company’s products are used in the treatment of multiple human indications including breast cancer, renal cell carcinoma, mantle cell lymphoma and pancreatic neuroendocrine tumours, Alzheimer’s, Parkinson’s and various ageing disorders. PAA is headquartered in Bentley, Western Australia, Australia.

For a complete picture of Monepantel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.